Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report-Reference-Cited by-同舟云学术

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report

Published:2013-11-26 Issue:1 Volume:6 Page:
ISSN:1756-0500
Container-title:BMC Research Notes
language:en
Short-container-title:BMC Res Notes

Author:

Rossing Henrik H,Grauslund Morten,Urbanska Edyta M,Melchior Linea C,Rask Charlotte K,Costa Junia C,Skov Birgit G,Sørensen Jens Benn,Santoni-Rugiu Eric

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/1756-0500-6-489.pdf

Reference22 articles.

1. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E: European cancer mortality predictions for the year 2012. Ann Oncol. 2012, 23: 1044-1052. 10.1093/annonc/mds024.

2. Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC: ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer. 2012, 48: 961-973. 10.1016/j.ejca.2012.02.001.

3. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007, 448: 561-566. 10.1038/nature05945.

4. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009, 27: 4247-4253. 10.1200/JCO.2009.22.6993.

5. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010, 363: 1693-1703. 10.1056/NEJMoa1006448.

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular tumor board–guided treatment of non-small-cell lung cancer with dual driver (ALK and EGFR) alterations;Cancer Research, Statistics, and Treatment;2022

2. Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL;Cancers;2021-11-29

3. ALK-Positive Non-Small Cell Lung Cancer; Potential Combination Drug Treatments;Current Cancer Drug Targets;2021-10

4. Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition;International Journal of Molecular Sciences;2020-04-19

5. Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country;Journal of Global Oncology;2019-12